CSIMarket
 


Fulcrum Therapeutics Inc   (FULC)
Other Ticker:  
 
 

FULC's Income from Cont. Operations Growth by Quarter and Year

Fulcrum Therapeutics Inc 's Income from Cont. Operations results by quarter and year




FULC Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 29.71 0.00 0.00
III Quarter September - -16.54 0.00 0.00
II Quarter June - -13.17 0.00 0.00
I Quarter March -18.45 0.00 0.00 0.00
FY   -18.45 0.00 - -



FULC Income from Cont. Operations first quarter 2020 Y/Y Growth Comment
Fulcrum Therapeutics Inc in the first quarter recorded loss from continued operations of $ -18.45 millions.

According to the results reported in the first quarter, Fulcrum Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Fulcrum Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter.




FULC Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Fulcrum Therapeutics Inc 's first quarter 2020 Income from Cont. Operations $ -18.45 millions FULC's Income Statement
Fulcrum Therapeutics Inc 's first quarter 2019 Income from Cont. Operations $ 0.00 millions Quarterly FULC's Income Statement
New: More FULC's historic Income from Cont. Operations Growth >>


FULC Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Fulcrum Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FULC's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2020 results of -18.45 millions by Fulcrum Therapeutics Inc come out even less good considering the loss from continued operations 29.71 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Fulcrum Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Fulcrum Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FULC's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2020 accomplishment of -18.45 millions by Fulcrum Therapeutics Inc come out even more unfavourable considering the loss from continued operations 29.71 millions a quarter before.

Within Major Pharmaceutical Preparations industry Fulcrum Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Fulcrum Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Fulcrum Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
Cumulative Income from Cont. Operations 12 Months Ending $ -18.45 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Fulcrum Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -18 millions in the Mar 31 2020 period.
The results are detiriorating as the cumulative loss from continued operations is inflating from $ 0 millions for the period from Dec 31 2019 to and $ 29.71 millions for the twelve months ending in the quarter a year ago.

Fulcrum Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Fulcrum Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -18 millions in the Mar 31 2020 period.
The business is detiriorating as the cumulative loss from continued operations is becoming larger from $ 0 millions in TTM ending quarter Dec 31 2019 and $ 29.71 millions for the twelve months ending in the quarter a year ago Arnav Kadam  told.

Fulcrum Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
FULC's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for FULC's Competitors
Income from Cont. Operations Growth for Fulcrum Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for FULC's Customers

You may also want to know
FULC's Annual Growth Rates FULC's Profitability Ratios FULC's Asset Turnover Ratio FULC's Dividend Growth
FULC's Roe FULC's Valuation Ratios FULC's Financial Strength Ratios FULC's Dividend Payout Ratio
FULC's Roa FULC's Inventory Turnover Ratio FULC's Growth Rates FULC's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2020
Biogen Inc -1.15 %$ -1.150 millions
Baxter International Inc -4.03 %$ -4.035 millions
Iradimed Corporation -4.14 %$ -4.137 millions
Alexion Pharmaceuticals Inc -5.15 %$ -5.154 millions
Hill rom Holdings Inc -5.25 %$ -5.253 millions
Atrion Corp -5.72 %$ -5.722 millions
U s Neurosurgical Holdings Inc -5.91 %$ -5.914 millions
Pra Health Sciences Inc -8.13 %$ -8.125 millions
Amgen Inc -8.38 %$ -8.384 millions
Charles River Laboratories International inc -8.71 %$ -8.711 millions
Phibro Animal Health Corp -9.08 %$ -9.078 millions
Lemaitre Vascular Inc -9.65 %$ -9.650 millions
Mettler Toledo International Inc -12.24 %$ -12.245 millions
Pfizer Inc -12.32 %$ -12.317 millions
Encompass Health Corporation -13.44 %$ -13.445 millions
Procyon Corp -13.98 %$ -13.982 millions
Haemonetics Corporation -15.41 %$ -15.412 millions
Orgenesis Inc -16.98 %$ -16.982 millions
Bio techne Corp -18.41 %$ -18.413 millions
Abbott Laboratories -19.05 %$ -19.048 millions
Bio rad Laboratories Inc -20.72 %$ -20.722 millions
Gilead Sciences Inc -21.85 %$ -21.850 millions
Illumina Inc -22.77 %$ -22.768 millions
Universal Health Services Inc -39.15 %$ -39.149 millions
Biotelemetry Inc -39.16 %$ -39.161 millions
Quest Diagnostics Inc -39.77 %$ -39.773 millions
Hca Healthcare Inc -40.90 %$ -40.898 millions
Nuvasive Inc -43.55 %$ -43.554 millions
National Vision Holdings Inc -44.10 %$ -44.105 millions
Icu Medical Inc -45.69 %$ -45.693 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

IGAP's Profile

Stock Price

IGAP's Financials

Business Description

Fundamentals

Charts & Quotes

IGAP's News

Suppliers

IGAP's Competitors

Customers & Markets

Economic Indicators

IGAP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071